Cvergenx
Tampa, US · Delaware corporation
CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.
Founders & leadership
JT
Javier Torres-Roca, M.D.Secretary & Treasurer
SE
Steven Eschrich, Ph.D.Chief Technology Officer
RF
Raymond F. VennarePresident and Chief Executive Officer
Board
MB
MaryDel BradyBoard director
Reported raises · per SEC filings
Form D private placements$390K disclosed across 1 of 3 rounds · 2011–2017
▶$2.5MofferedJul 2017 · OtherRule 506(b)
▶$2.5MofferedJul 2017 · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raymond F. VennareExecutive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Steven Eschrich, Ph.D.Executive Officer, Director
- Offering amount
- $2.5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KofferedMay 2016 · OtherRule 506(c)
▶$500KofferedMay 2016 · Other
Rule 506(c)Officers, directors & promoters on the filing
- Steven Eschrich, Ph.D.Executive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Raymond F. VennareExecutive Officer, Director
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$390KraisedMay 2016 · 10 investors · OtherRule 506(b)
▶$390KraisedMay 2016 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raymond F. VennareExecutive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Steven Eschrich, Ph.D.Executive Officer, Director
- MaryDel BradyDirector
- Offering amount
- $390K
- Amount sold
- $390K
- First sale
- Apr 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cvergenx do?
- CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.
- Who founded Cvergenx?
- Cvergenx was founded by Javier Torres-Roca, M.D., Steven Eschrich, Ph.D..
- How much funding has Cvergenx raised?
- Cvergenx has disclosed $390K raised across 1 of its 3 known rounds.
- Where is Cvergenx headquartered?
- Cvergenx is headquartered in Tampa, US.